19
November 2024
MANOLETE PARTNERS
PLC
("Manolete" or the "Company")
Half-year results for the six
months ended 30 September 2024
Manolete (AIM:MANO), the leading
UK-listed insolvency litigation financing
company, today announces
its unaudited results for the six months ended 30 September
2024.
Steven Cooklin, Chief Executive Officer,
commented:
"These are a strong set of results,
particularly in terms of organic cash generation. In this six-month
period, gross cash collected rose 63% to a new record at £14.3m.
That strong organic cash generation comfortably covered all cash
operating costs, as well as all cash costs of financing the ongoing
portfolio of 413 live cases, enabling Manolete to reduce net debt
by £1.25m to £11.9m as at 30 September 2024.
As a consequence of Manolete
completing a record number of 137 case completions, realised
revenues rose by 60% to a further record high of £15m. That is a
strong indicator of further, and similarly high levels, of
near-term future cash generation. A record pipeline of 437 new case
investment opportunities were received in this latest six-month
trading period, underpinning the further strong growth prospects
for the business.
The record £14.3.m gross cash was
collected from 253 separate completed cases, highlighting the
highly granular and diversified profile of Manolete's income
stream.
Manolete has generated a Compound
Average Growth Rate of 39% in gross cash receipts over the last
five H1 trading periods: from H1 FY20 up to and including the
current H1 FY25. The resilience of the Manolete business model,
even after the extraordinary pressures presented by the extended
Covid period, is now clear to see.
This generated net cash income of
£7.6m in H1 FY25 (after payment of all legal costs and all payments
made to the numerous insolvent estates on those completed cases),
an increase of 66% over the comparative six-month period for the
prior year. Net cash income not only exceeded by £4.5m all the cash
overheads required to run the Company, it also exceeded all the
costs of running Manolete's ongoing 413 cases, including the 126
new case investments made in H1 FY25.
The Company recorded its highest
ever realised revenues for H1 FY25 of £15.0m, exceeding H1 FY24 by
60%. On average, Manolete receives all the cash owed to it by the
defendants of completed cases within approximately 12 months of the
cases being legally completed. This impressive 60% rise in realised
revenues therefore provides good near-term visibility for a
continuation of Manolete's strong, and well-established, track
record of organic, operational cash generation.
New case investment opportunities
arise daily from our wide-ranging, proprietary, UK referral network
of insolvency practitioner firms and specialist insolvency and
restructuring solicitor practices. We are delighted to report that
the referrals for H1 FY25 reached a new H1 company record of 437. A
27% higher volume than in H1 FY24, which was itself a new record
for the Company this time last year. That points to a very healthy
pipeline as we move forward into the second half of the trading
year."
Financial highlights:
· Total
revenues increased by 28% to £14.4m from H1 FY24 (£11.2m) as a
result of the outstanding delivery of realised revenues generated
in the six months to 30th September 2024.
· Realised revenues achieved a record level of £15.0m in H1
FY25, a notable increase of 60% on H1 FY24 (£9.4m). This provides
good visibility of near-term further strong cash generation, as on
average Manolete collects all cash on settled cases within
approximately 12 months of the legal settlement of those
cases
· Unrealised revenue in H1 FY25 was £(633k) compared to £1.8m
for the comparative H1 FY24. This was due to: (1) the record number
of 137 case completions in H1 FY25, which resulted in a beneficial
movement from Unrealised revenues to Realised revenues; and (2) the
current lower average fair value of new case investments made
relative to the higher fair value of the completed cases. The
latter point also explains the main reason for the marginally lower
gross profit reported of £4.4m in this period, H1 FY25, compared to
£5.0m in H1 FY24.
· EBIT
for H1 FY25 was £0.7m compared to H1 FY24 of £1.6m. As well as the
reduced Gross profit contribution explained above, staff costs
increased by £165k to £2.3m and based on the standard formula used
by the Company to calculate Expected Credit Losses, ("ECL"),
generated a charge of £140k (H1 FY24: £nil) due to trade debtors
rising to £26.8m as at 30 September 2024, compared to £21.7m as at
30 September 2023. The trade debtor increase was driven by the
outstanding record level of £15.0m Realised revenues achieved in H1
FY25.
· Loss
Before Tax was (£0.2m) compared to a Profit Before Tax of £0.9m in
H1 FY24, due to the above factors together with a lower corporation
tax charge being largely offset by higher interest
costs.
· Basic
earnings per share (0.5) pence (H1 FY24: 1.4 pence).
· Gross
cash generated from completed cases increased 63% to £14.3m in the
6 months to 30 September 2024 (H1 FY24: £8.7m). 5-year H1 CAGR:
39%.
· Cash
income from completed cases after payments of all legal costs and
payments to Insolvent Estates rose by 66% to £7.6m (H1 FY24:
£4.6m). 5-year H1 CAGR: 46%.
· Net
cashflow after all operating costs but before new case investments
rose by 193% to £4.5m (H1 FY24: £1.5m). 5-year H1 CAGR:
126%.
· Net
assets as at 30 September 2024 were £40.5m (H1 FY24: £39.8m). Net
debt was reduced to £11.9m and comprises borrowings of £12.5m,
offset by cash balances of £0.6m. (Net debt as 31 March 2024 was
£12.3m.)
· £5m of
the £17.5m HSBC Revolving Credit Facility remains available for
use, as at 30 September 2024. That figure does not take into
account the Company's available cash balances referred to
above.
Operational highlights:
· Ongoing delivery of record realised returns: 137 case
completions in H1 FY25 representing a 18% increase (116 case
realisations in H1 FY24), generating gross settlement proceeds
receivable of £13.9m for H1 FY25, which is 51% higher than the H1
FY24 figure of £9.2m. This very strong increase in case settlements
provides visibility for further high levels of cash income, as it
takes the Company, on average, around 12 months to collect in all
cash from previously completed cases.
· The
average realised revenue per completed case ("ARRCC") for H1 FY25
was £109k, compared to the ARRCC of £81k for H1 FY24. That 35%
increase in ARRCC is an important and an encouraging Key
Performance Indicator for the Company. Before the onset and impact
of the Covid pandemic in 2020, the Company was achieving an ARRCC
of approximately £200k. Progress back to that ARRCC level, together
with the Company maintaining its recent high case acquisition and
case completion volumes, would lead to a material transformation of
Company profitability.
· The
137 cases completed in H1 FY25 had an average case duration of 15.7
months. This was higher than the average case duration of 11.5
months for the 118 cases completed in H1 FY24, because in H1 FY25
Manolete was able to complete a relatively higher number of older
cases, as evidenced by the Vintages Table below.
· Average case duration across Manolete's full lifetime
portfolio of 1,064 completed cases, as at 30 September 2024 was
13.3 months (H1 FY24: 12.7 months).
· Excluding the Barclays Bounce Back Loan ("BBL") pilot cases,
new case investments remained at historically elevated levels of
126 for H1 FY25 (H1 FY24: 146 new case investments).
· New
case enquiries (again excluding just two Barclays BBL pilot cases
from the H1 FY24 figure) achieved another new Company record of 437
in H1 FY25, 27% higher than the H1 FY24 figure of 343. This
excellent KPI is a strong indicator of future business performance
and activity levels.
· Stable
portfolio of live cases: 413 in progress as at 30 September 2024
(417 as at 30 September 2023) which includes 35 live
BBLs.
· Excluding the Truck Cartel cases, all vintages up to and
including the 2019 vintage have now been fully, and legally
completed. Only one case remains ongoing in the 2020 vintage. 72%
of the Company's live cases have been signed in the last 18
months.
· The
Truck Cartel cases continue to progress well. As previously
reported, settlement discussions, to varying degrees of progress,
continue with a number of Defendant manufacturers. Further updates
will be provided as concrete outcomes emerge.
· The
Company awaits the appointment of the new Labour Government's Covid
Corruption Commissioner and hopes that appointment will set the
clear direction of any further potential material involvement for
Manolete in the Government's BBL recovery programme.
· The
Board proposes no interim dividend for H1 FY25 (H1 FY24:
£nil).
For further information, please
contact:
Manolete Partners Plc via Instinctif
Partners
|
Steven Cooklin (Chief Executive
Officer)
|
Canaccord Genuity Limited (NOMAD and
Sole Broker)
|
Emma Gabriel +44 (0)207
523 8000
|
Chief Executive Officer's Statement
Introduction
I am pleased to present our
unaudited statements for the six months ended 30 September 2024
("H1 FY25").
Manolete is the leading UK quoted
company in the insolvency litigation finance market, a sector which
plays an important role in returning funds to creditors,
particularly HMRC.
The UK Insolvency Market
April 2022 was a major inflexion
point for Manolete. The Conservative Government of the time ended
its Covid era temporary suspension of a number of significant UK
insolvency laws and also curtailed its very significant financial
support provided to UK companies, causing the UK insolvency market
to rebound very positively. In addition, UK companies were faced
with a new economic environment, marked by high inflation, high
interest rates and supply chain issues, factors which still impact
UK businesses today. Added to those pressures, businesses are now
also challenged by the recently announced increases in Employer
National Insurance Contribution rates, above inflation labour pay
rises and more stringent labour laws.
Source: UK Insolvency Service 18
October 2024
The overall UK insolvency market is
now the most buoyant it has been since the 2008/09 financial
crisis, with the level of Creditor Voluntary Liquidations ("CVLs")
- by far the largest element of the insolvency market - at its
highest levels recorded by the Insolvency Service since 1960. As
anticipated by the Company, it can be seen from the graphic above,
these high levels of insolvency activity persist. The Board of
Manolete believes that these conditions will continue to drive
elevated levels of UK insolvencies, for the reasonably foreseeable
future.
Company Performance
As the leading operator in the
specialist area of UK Insolvency Litigation Finance, it is
unsurprising that the unprecedented gyrations in the UK insolvency
market, over the last five years, are mirrored in Manolete's
financial and operating performance, albeit with an average
12-month time delay.
New Case Enquiries
The new case enquiries graphic
depicted below, represents the levels of new case investment
opportunities referred to Manolete between 1 April 2018 and up to
and including 30 September 2024. The graph closely mirrors the
shape of the UK insolvency market trends, shown above, with a
relatively short time lag, as Office Holders (Liquidators,
Administrators and Trustees in Bankruptcy) naturally require a
reasonable period of time to investigate their new appointments
before they are in position to present potential case opportunities
to Manolete.
Source: Company Data
For this latest interim period, new
case enquiries were 27% higher than the corresponding first half
period last year (please note that in order to best present the
important underlying, sustainable trends, we have excluded the
large block of 106 new case enquiries related to the Barclays BBL
Pilot in H1 FY23 and the two further Barclays BBL Pilot case
enquiries in H1 FY24, as there is no guarantee that this activity
was more than an exceptional one-off project. Further details
follow below.
The 437 new case enquiries in H1
FY25 were 13% ahead of the Company's previous record of 388 in H2
FY24 and far in excess of the levels experienced before the
pandemic impact in H2 FY21.
New Signed Cases
In H1 FY25, the level of new signed
case investments continued to exceed the pre-pandemic level by some
margin (as above we have excluded the exceptional Barclays BBL
Pilot cases. One further Barclays BBL Pilot case was signed in H1
FY25).
The single anomaly in the otherwise
strong key performance indicators, was that the first quarter of
FY25 delivered just 44 new signed cases. Much more positively, Q2
FY25 rebounded very strongly to 81 and that positive trend has
continued into Q3 FY25, with 31 new case investments signed in
October 2024. As in prior years the lower volumes in Q1 FY25 were
due to Insolvency Practitioners ("IPs") and their staff being very
busy attending to Members Voluntary Liquidations ("MVLs"), at
around the time that the tax year ended on 5 April each year. MVLs
are solvent liquidations of companies by their shareholders (rather
than creditors) as they usually relate to tax planning issues.
Furthermore, this factor was exacerbated this year, because of the
further certainty of a UK General Election looming at some time
later in the calendar year 2024. Therefore the MVL activity appears
to have been exceptionally, but understandably, strong in Q1 FY25,
leading to a short temporary loss of IP focus on insolvency
litigation claims. It was pleasing to see a very strong recovery of
this key performance indictor in Q2 FY25 and beyond.
Case Completions
H1 FY25 saw an outstanding, record
level of 137 full legal case completion, an 18% increase over the
116 case completions recorded for H1 FY24.
The aggregate gross settlement
proceeds receivable from those 137 legally binding case completions
in H1 FY25 was an impressive £13.9m as that is 44% higher than the
H1 FY24 figure of £9.2m. This very strong increase in the aggregate
value of case settlements is a highly reliable indicator for
future, near term, cash collection, as it takes the Company, on
average, around 12 months to collect in all legally agreed cash
receivables on its completed cases.
The Manolete Board has been keen to
highlight that as the Company emerged from the Covid downturn,
newly signed case volumes recovered very positively but the average
realised revenue value per case was significantly lower than
Manolete had been achieving prior to the onset of the Covid
pandemic. This was because the first large wave of high insolvency
levels featured a disproportionately larger number of smaller UK
companies as they typically have less robust balance sheets, fewer
financing options and are therefore less likely to withstand
insolvency pressures. The level of UK Administration insolvencies
(a good indicator of larger company insolvencies as they favour the
Administration insolvency route) has only reached the higher
pre-pandemic levels in the last 9 months or so and the rate of
increase in Administrations has been far more gradual than the very
sharp increase in CVLs, the latter being the typical route to
insolvency for smaller and medium size companies. The size of claim
referred to Manolete, ends to be determined by the size of economic
entity from which the claim emanates.
Prior to the start of Covid in
March/April 2020, Manolete achieved an average realised revenue per
completed case ("ARRCC") of around £200k. That is close to the
approximate market norm for the size of an average UK insolvency
litigation case where cases tend to settle at approximately half of
£500k average headline claim value. It is therefore encouraging
that in H1 FY25 the ARRCC was £109k, a 35% increase from HY FY24
ARRCC of £81k. For the full 12 months of FY24 the ARRCC was £94k.
Therefore, the H1 FY25 ARRCC is 16% above the full 12-month FY24
ARRCC. These are important and encouraging but still early trends
pointing to an increasing ARRCC. The ARRCC is a highly important
factor in determining the financial outturn of the Company for any
given period. In any analysis of any sector of the Law, one should
not draw definitive conclusions based on the results of just six
months data. This trend requires analysis over a longer and
statistically more significant period of time.
Average case durations (the time it
takes from Manolete signing a new case investment to legally
completing it) for the 137 cases completed in H1 FY25 increased to
15.7 months from 11.5 months for H1 FY24. The H1 FY25 period
featured the welcome completion of a relatively larger number of
older vintage cases compared to the H1 FY24 period.
Revenues and Profit
The Company recorded its highest
ever realised revenues of £15.0m in H1 FY25, exceeding H1 FY24's
£9.4m by an impressive 60%. On average, Manolete receives all the
cash owed to it by the defendants of completed cases within around
12 months of the case being legally completed. That provides
excellent near-term visibility and therefore a reasonable
expectation for the continuation of the Company's strong and now
clearly well-established track record of cash
generation.
The Company's H1 FY25 movement on
unrealised revenues (which are also technically the same as the
Company's unrealised gross profit) showed a negative movement of
£633k compared to a positive £1.8m movement in H1 FY24. The primary
reasons for this were: (1) the record level of case completions in
H1 FY25 which cause a beneficial movement from "unrealised" to
"realised" revenues and "unrealised" to "realised" gross profit;
(2) the ARRCC factor explained above. The new cases being added to
the Company's case portfolio have on average been the (internally
estimated) relatively smaller cases compared to those many cases
that were completed in the last 6-month trading period. However, as
stated above, the Company has not only achieved strong levels of
new signed cases, there are also early indications of a recovery in
ARRCC, back towards the attractive pre-pandemic ARRCC
level.
Referring now to the Company's
reported Operating Profit: while the CFO Report below analyses this
in greater detail, it is the product of the multiple factors
covered above that combine to produce the operating profit of £658k
for H1 FY25, a 58% decrease compared to the £1.6m reported for H1
FY24. The main factor supressing the current level of profitability
continues to be the lower fair value our in-house legal team (who
are the principal drivers of the fair value of the in-process, live
cases in Manolete's case investment portfolio at any one time)
attribute to those more recent ongoing cases, compared to the
comparative previous financial period of H1 FY24.
A continued improvement in the
Company's ARRCC and a sustained performance in the already high
levels of case volumes, are the key to bringing a strong and
sustained recovery in the Company's profitability.
Cash Generation
Manolete's cash generation
performance over the last several years and, particularly this most
recent H1 FY25 period, is the Company's most outstanding and
important achievement as cash generation is the paramount
performance benchmark for most corporate entities.
(i)
Gross Cash
In the first six months of this
current trading year, Manolete reported gross cash received from
completed cases of £14.3m, an increase of 63%, compared to the
corresponding period H1 FY24 of £8.7m.
Starting from the first full
financial year following the Company's IPO on AIM in December 2018
(FY20), Manolete's gross cash generation is now very well
established. Over the six-year period of first half trading results
that are covered by the graph below, the Company has delivered an
impressive Compound Average Growth Rate ("CAGR") for gross cash
collected of 39%.
Source: published accounts of
Manolete Partners Plc.
Note*: H1 FY23 has been adjusted to
exclude an exceptionally large funded, one-off case that generated
gross cash of £9.5m
(ii)
Net Cash Received
A similarly impressive picture
emerges from an analysis of Manolete's net cash income collected
from completed cases (which is the gross cash referred to
immediately above, but after the deduction of all payments of legal
costs and payments to Insolvent Estates on the completed cases in
each respective period - defined here as "Net Cash Received"). For
H1 FY25 Manolete reported Net Cash Received from completed cases of
£7.6m, an increase of 66% compared to the corresponding H1 FY24 of
£4.6m. It is worth noting that the H1 FY25 Net Cash Received figure
of £7.6m exceeds the £5.9m of full year cash operating costs of
running the Company throughout the whole 12 months of FY24. The
Board is confident that the cash costs of operating the Company in
this current full year of FY25 will be similar to those of FY24.
Therefore, the first six months of Manolete's FY25 have generated
significantly more cash than the costs of running the Company for
the entire 12 months - an excellent milestone
achievement.
Source: published accounts of
Manolete Partners Plc.
Note*: H1 FY23 has been adjusted to
exclude an exceptionally large funded, one-off case that generated
gross cash of £9.5m
Over the six-year period of first
half trading results covered by the graph above, the Company has
delivered an impressive CAGR for Net Cash Received of
46%.
(iii)
Net Operating Cash Received
Finally, one can see a similarly
strong and consistent trend when analysing Manolete's cash received
before new case investments. This is the Net Cash Received, as
previously defined above, less all cash costs of operating the
entire Company in each of the respective first six-month periods of
the relevant financial years. This is defined here as "Net
Operating Cash Received".
For H1 FY25 Manolete reported Net
Operating Cash Received of £4.4m, an increase of 193% compared to
the corresponding H1 FY24 of £1.5m.
As can be seen from the graph below,
over the last four years, the Company has been consistently
delivering positive Net Operating Cash Received in the first half
trading results during that period. The Company's CAGR for Net
Operating Cash Received over the last four years is
126%.
Source: published accounts of
Manolete Partners Plc.
Note*: H1 FY23 has been adjusted to
exclude an exceptionally large funded, one-off case that generated
gross cash of £9.5m
For H1 FY25, the Net Operating Cash
Received of £4.4m exceeded the costs of financing the 413 ongoing
live cases, which included the acquisition of 126 new case
investments (including one new Barclays BBL Pilot case). That high
level of organically generated cash was then used to reduce the
Company's net debt.
Net Debt Reduced
HSBC provides the Company with a
£17.5m Revolving Credit Facility ("RCF"). The strong cash
generation delivered in H1 FY25 enabled the Company to repay HSBC a
net £1.25m (by comparison, in H1 FY24, the Company increased its
drawings from the HSBC RCF by an additional £2.5m). The Company's
Net Debt as at 30 September 2024 was reduced to £11.9m (at 30
September 2023 Net Debt was £12.0m and at the most recent year
ended 31 March 2024, Net Debt was £12.3m).
Vintages Table
This table highlights some of the
key performance features of Manolete's business model. In H1 FY25,
our in-house legal team was able to complete several of the few
remaining older cases that we had in the investment portfolio. That had an effect of lengthening
the average duration on cases completed in H1 FY25. However,
looking at the investment portfolio as a whole, 72% of the current
in-process cases were signed in the last 18 months, which
demonstrates Manolete's impressive ability to realise cases, and
generate cash from them for further reinvestment in our specialist
sector. That delivers consistently very high returns on capital
employed. Some of the key features to note from the table below
include:
1.
Consistently high IRRs across 1,064 completed cases.
2. Fast case
completions, at an average of 13.3 months per case (H1 FY24: 12.7
months per case) from the date of signing the investment agreement
to the date that the case is legally completed. Cash tends to be
collected, on average, over the following 12 months (H1 FY24: 12
months).
3. All cases
completed for the 2019 vintage and earlier.
4. Only one
of the 141 cases invested in the 2020 vintage remains
open.
Case Vintages as at 30 September 2024
Strategy, Outlook and Team
The Company ended H1 FY25 with 413
live cases in-progress (417 live cases at the end of H1 FY24). The
Directors believe that given the challenging prevalent economic
environment, featuring relatively high inflation, significantly
higher interest rates and historic record high levels of UK
insolvencies, the Company is well set to continue its growth
trajectory.
From January 2023, the Company
started to take assignments of cases from the specialist recovery
work it is undertaking with Barclays Bank plc on a range of
defaulted Bounce Back Loans ("BBLs") issued by Barclays. The
Company awaits the new Labour Government's appointment of a Covid
Corruption Commissioner. Following that appointment, the Company
expects to learn whether it is likely, or not, to have any further
material involvement in the recovery of defaulted BBLs.
As previously, and recently,
reported, we have a number of potential settlement discussions
ongoing, at varying levels of progress, relating to our Truck
Cartel cases. Where settlements with truck manufacturer defendant
companies are not possible, Manolete will progress those cases to
trial.
Our Board is always very grateful to
the high quality, dedicated team of its colleagues, across all the
departments of Manolete.
Dividend
The Board recommends no interim
dividend be proposed for the six months to 30 September
2024.
Steven Cooklin
Chief Executive Officer
Chief Financial Officer's Review
I am pleased to give my review of
the Company's unaudited results for the half year to 30 September
2024.
|
|
6 months
ended 30
September
2024
|
6 months
ended 30
September
2023
|
|
|
Unaudited
|
Unaudited
|
|
|
£'000s
|
£'000s
|
|
|
|
|
Revenue
|
|
14,402
|
11,230
|
Cost of sales
|
|
(10,013)
|
(6,234)
|
Gross profit
|
|
4,389
|
4,996
|
|
|
|
|
Administrative expenses
|
|
(3,731)
|
(3,437)
|
Operating profit
|
|
658
|
1,559
|
|
|
|
|
KPI's
|
|
|
|
Gross profit margin %
|
|
30%
|
44%
|
Operating profit margin %
|
|
5%
|
14%
|
New cases (#)
|
|
126
|
179
|
Completed cases (#)
|
|
137
|
116
|
Live cases at period end (#)
|
|
413
|
417
|
The financial results for the 6
months to 30 September 2024 (H1 FY25) report an Operating profit of
£0.7m (H1 FY24 £1.6m). Revenue in H1 FY25 was reported as £14.4m
(H1 FY24 £11.2m) an increase of 28% on the same period in the prior
year.
Operationally, the business
performed strongly and completed 137 cases in the 6-month period to
30 September 2024 (116 cases, H1 FY24) and signed, including
Barclays BBL cases, 126 new cases (179 new cases, H1 FY24) and
continues to realise cash proceeds from both historic and current
year completed cases.
|
|
6 months
ended 30
September
2024
|
6 months
ended 30
September
2023
|
|
|
Unaudited
|
Unaudited
|
|
|
£'000s
|
£'000s
|
|
|
|
|
Realised revenue
|
|
15,035
|
9,401
|
Unrealised revenue
|
|
(633)
|
1,829
|
Revenue
|
|
14,402
|
11,230
|
|
|
|
|
Mix %
|
|
|
|
Realised revenue
|
|
104%
|
84%
|
Unrealised revenue
|
|
(4%)
|
16%
|
Revenue increased from £11.2m in H1
FY24 to £14.4m in H1 FY25, an increase of 28%, which was a result
of a higher number and value of case completions in the 6-month
period resulting in a record level of realised revenue. We look at
each realised and unrealised revenue separately:
Realised revenue increased from
£9.4m H1 FY24 to £15.0m in H1 FY25, an increase of 60%. This was a
result of a higher number and value of completed cases in the
6-month period, 137 completed cases at an average realised value of
£109k per case (H1 FY24, 116 completed cases at an average realised
value of £81k per case).
Unrealised revenue decreased to
(£0.6m) H1 FY25 compared with a positive £1.8m in H1 FY24. This was
due to a high value of completions (a negative to unrealised
revenue) not being fully replaced by the value of new cases signed
in the 6-month period.
|
|
6 months
ended 30
September
2024
|
6 months
ended 30
September
2023
|
|
|
Unaudited
|
Unaudited
|
|
|
£'000s
|
£'000s
|
|
|
|
|
Realised gross profit
|
|
5,022
|
3,167
|
Unrealised gross
(loss)/profit
|
|
(633)
|
1,829
|
Gross profit
|
|
4,389
|
4,996
|
|
|
|
|
|
|
|
|
Margin %
|
|
|
|
Realised gross profit
|
|
33%
|
34%
|
Unrealised gross profit
|
|
(100%)
|
100%
|
Gross profit margin %
|
|
30%
|
44%
|
Gross profit decreased from £5.0m in
H1 FY24 to £4.4m in H1 FY25, primarily due to the positive
contribution of Unrealised revenue in the prior year period. Once
again, we review realised and unrealised gross profit
separately.
Realised gross profit increased to
£5.0m H1 FY25 (£3.2m H1 FY24), due to the large number of
completions within the 6-month period. Realised gross profit
margins remained stable at 33% H1 FY25 compared to 34% H1
FY24.
Unrealised gross profit of (£0.6m)
H1 FY25 was a result of the large number of case completions (a
deduction from unrealised revenue as they are transferred to
realised revenue) which were not fully matched by new cases
signed.
Administrative expenses
Administrative expenses increased by
8.6% to £3.7m in the six months to 30 September 2024 (H1 FY24:
£3.4m) which is principally attributable to an increase in staff
costs by £165k, a result of annual staff salary
increases.
Increase in bad debt expense
represents an increase in the expected credit loss in line with an
increase in gross debtors as well as an in-depth review into the
Company's older debts.
Statutory operating profit
Operating profit decreased to £0.7m
in H1 FY25 (H1 FY24: £1.6m) with an operating profit margin of 5%
(H1 FY24: 14%).
Finance expense increased to £859k
in H1 FY25 (H1 FY24: £647k) as base interest rates have been at a
higher average rate than in the 6-month period to 30 September
2023.
No interim dividend is proposed for
FY25 (FY24 interim dividend, nil).
The Company was managing 413 live
case investments (including Cartel cases) as at 30 September 2024,
compared to 417 live cases (including Cartel cases) as at 30
September 2023. The total investment in cases amounted to £39.5m at
30 September 2024 (30 September 2023 value of £39.4m).
Investments in cases are shown at
fair value, based on the Company's estimate of the likely future
realised gross profit. Management, following discussion with the
in-house legal team, on a case by case basis, amend the valuations
of cases each month to accurately reflect management's view of fair
value. In addition, at year end reporting periods, a sample of
material valuations are corroborated with the external lawyers
working on the case who provide updated legal opinions as to the
current status of the case. The Company does not capitalise any of
its internal costs, these are fully expensed to the Statement of
Comprehensive income.
Trade and other receivables
Trade and other receivables have
increased to £29.3m H1 FY25 from £24.3m H1 FY24, an increase of
20%, driven by a high number and value of case completions. This
amount is net of provision for bad debts.
|
|
6 months
ended 30
September
2024
|
6 months
ended 30
September
2023
|
|
|
Unaudited
|
Unaudited
|
|
|
£'000s
|
£'000s
|
|
|
|
|
Gross cash receipts
|
|
14,271
|
8,739
|
IP share & legal costs on
completed cases
|
|
(6,678)
|
(4,163)
|
Cashflows from completed cases
|
|
7,593
|
4,576
|
|
|
|
|
Overheads
|
|
(3,145)
|
(3,112)
|
Net
cash generated from operations before investment in cases and
corporation tax
|
|
4,448
|
1,464
|
|
|
|
|
Corporation tax
|
|
-
|
-
|
Investment in cases
|
|
(3,306)
|
(3,193)
|
Net
cash generated from / (used in) operations
|
|
1,142
|
(1,729)
|
Gross cash receipts of £14.3m in H1
FY25 (£8.7m H1 FY24) represents a strong increase in cash
generation in comparison with H1 FY24.
Cash generation was positive after
payment of IP share and external legal costs on those completed
cases and after payment of overheads of (£3.1m) and after
investment in new and existing cases.
In this 6-month period, we only
utilised our internally generated cash resources to invest in new
and existing cases.
The Company has Net debt of £11.9m
with a drawn down balance of £12.5m (£13.0m H1 FY24) of its £17.5m
HSBC loan facility as at 30 September 2024 and continues to deploy
loan capital, if required, to finance investment in cases. During
H1 FY25 the Company repaid a net £1.25m of its HSBC loan facility
(drew down £2.5m H1 FY24). The Company held cash reserves of £0.6m
as at 30th September 2024 and had £5.0m available of the
£17.5m HSBC facility. This facility and cash reserves will be used
to fund future growth in case volumes. The HSBC loan refinancing is
due in June 2025, we are scheduled to undertake discussions with
HSBC from January 2025, we are also in early-stage discussions with
potential other lenders.
Mark Tavener
Chief Financial Officer
Unaudited Statement of Comprehensive Income for the period
ended 30 September 2024
|
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
Note
|
£'000s
|
|
£'000s
|
£'000s
|
|
|
|
|
|
|
Revenue
|
3
|
14,402
|
|
11,230
|
26,295
|
|
|
|
|
|
|
Cost of sales
|
|
(10,013)
|
|
(6,234)
|
(16,150)
|
Gross Profit / (Loss)
|
|
4,389
|
|
4,996
|
10,145
|
|
|
|
|
|
|
Administrative expenses
|
4
|
(3,731)
|
|
(3,437)
|
(7,644)
|
Operating Profit / (Loss)
|
|
658
|
|
1,559
|
2,501
|
|
|
|
|
|
|
Finance income
|
|
16
|
|
7
|
16
|
Finance expense
|
5
|
(859)
|
|
(647)
|
(1,479)
|
Profit / (Loss) before tax
|
|
(185)
|
|
920
|
1,038
|
|
|
|
|
|
|
Taxation
|
|
(33)
|
|
(295)
|
(105)
|
Profit / (Loss) and total comprehensive income for the year
attributable to the equity owners of the Company
|
|
(218)
|
|
625
|
933
|
|
|
|
|
|
|
Earnings per share attributable to equity owners of the
Company
|
|
|
|
|
|
|
|
|
|
|
|
Basic (£ per share)
|
11
|
(0.49p)
|
|
1.43p
|
2.11p
|
Diluted (£ per share)
|
11
|
(0.49p)
|
|
1.36p
|
2.07p
|
The above results were derived from
continuing operations.
Unaudited Statement of Financial Position at 30 September
2024
Company Number: 07660874
|
|
30 September
2024
|
|
30
September 2023
|
31 March
2024
|
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
Note
|
£'000s
|
|
£'000s
|
£'000s
|
Non-current assets
|
|
|
|
|
|
Investments
|
6
|
11,291
|
|
13,530
|
11,293
|
Trade and other
receivables
|
9
|
12,078
|
|
11,606
|
14,203
|
Deferred tax asset
|
|
1,093
|
|
137
|
938
|
Total non-current assets
|
|
24,462
|
|
25,273
|
26,434
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
Investments
|
6
|
28,251
|
|
25,905
|
28,903
|
Trade and other
receivables
|
9
|
17,207
|
|
12,700
|
15,077
|
Corporation tax asset
|
|
-
|
|
470
|
-
|
Cash and cash equivalents
|
|
636
|
|
949
|
1,452
|
Total current assets
|
|
46,094
|
|
40,024
|
45,432
|
|
|
|
|
|
|
Total assets
|
|
70,556
|
|
65,297
|
71,866
|
|
|
|
|
|
|
EQUITY AND LIABILITIES
|
|
|
|
|
|
Equity
|
|
|
|
|
|
Share capital
|
|
175
|
|
175
|
175
|
Share premium
|
|
157
|
|
157
|
157
|
Share based payment
reserve
|
|
1,351
|
|
742
|
1,076
|
Retained earnings
|
|
38,845
|
|
38,755
|
39,063
|
Total equity attributable to the
equity owners of the company
|
|
40,528
|
|
39,829
|
40,471
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
Trade and other payables
|
10
|
7,643
|
|
7,019
|
8,434
|
Borrowings
|
|
12,500
|
|
12,928
|
13,726
|
Total non-current
liabilities
|
|
20,143
|
|
19,947
|
22,160
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Trade and other payables
|
10
|
9,781
|
|
5,521
|
9,235
|
Current tax liabilities
|
|
104
|
|
-
|
-
|
Total current liabilities
|
|
9,885
|
|
5,521
|
9,235
|
Total liabilities
|
|
30,028
|
|
25,468
|
31,395
|
|
|
|
|
|
|
Total equity and liabilities
|
|
70,556
|
|
65,297
|
71,866
|
The interim statements were approved
by the Board of Directors and authorised for issue on 19 November
2024.
Unaudited Statement of Changes in Equity for the period ended
30 September 2024
|
Share
Capital
|
Share
Premium
|
Share based payment
reserve
|
Retained
Earnings
|
Total
Equity
|
|
£000s
|
£000s
|
£000s
|
£000s
|
£000s
|
|
|
|
|
|
|
As
at 1 April 2023 (unaudited)
|
175
|
157
|
699
|
38,130
|
39,161
|
|
|
|
|
|
|
Comprehensive Income
|
|
|
|
|
|
Profit and total comprehensive
income
|
-
|
-
|
-
|
625
|
625
|
|
|
|
|
|
|
Transactions with owners
|
|
|
|
|
|
Share based payment
expense
|
-
|
-
|
144
|
-
|
144
|
Share based payments
exercised
|
-
|
-
|
-
|
|
-
|
Deferred tax on share-based
payments
|
-
|
-
|
(101)
|
-
|
(101)
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
As
at 30 September 2023 (unaudited)
|
175
|
157
|
742
|
38,755
|
39,829
|
|
|
|
|
|
|
Comprehensive Income
|
|
|
|
|
|
Profit and total comprehensive
income
|
-
|
-
|
-
|
308
|
308
|
|
|
|
|
|
|
Transactions with owners
|
|
|
|
|
|
Share based payment
expense
|
-
|
-
|
192
|
-
|
192
|
Share based payments
exercised
|
-
|
-
|
-
|
-
|
-
|
Deferred tax on share-based
payments
|
-
|
-
|
142
|
-
|
142
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
As
at 31 March 2024 (audited)
|
175
|
157
|
1,076
|
39,063
|
40,471
|
|
|
|
|
|
|
Comprehensive Income
|
|
|
|
|
|
Loss and total comprehensive
income
|
-
|
-
|
-
|
(218)
|
(218)
|
|
|
|
|
|
|
Transactions with owners
|
|
|
|
|
|
Share based payment
expense
|
-
|
-
|
191
|
-
|
191
|
Share based payments
exercised
|
-
|
-
|
-
|
-
|
-
|
Deferred tax on share-based
payments
|
-
|
-
|
84
|
-
|
84
|
Dividends
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
As
at 30 September 2024 (unaudited)
|
175
|
157
|
1,351
|
38,845
|
40,528
|
|
|
|
|
|
| |
Unaudited Statement of Cashflows for the period ended 30
September 2024
|
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year ended 31 March
2024
|
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
Note
|
£'000s
|
|
£'000s
|
£'000s
|
|
|
|
|
|
|
(Loss)/ Profit before tax
|
|
(185)
|
|
920
|
1,038
|
|
|
|
|
|
|
Adjustments for other operating items:
|
|
|
|
|
|
Adjustments for non-cash
items
|
8
|
4,993
|
|
4,895
|
4,420
|
Operating cashflows before movements in working
capital
|
|
4,808
|
|
5,815
|
5,458
|
|
|
|
|
|
|
Changes in working capital:
|
|
|
|
|
|
Net (decrease) / increase in trade
and other receivables
|
|
(5)
|
|
72
|
(4,901)
|
Net (decrease) / increase in trade
and other payables
|
|
(355)
|
|
(531)
|
4,408
|
Net
cash generated from operations before corporation tax and
investment in cases
|
|
4,448
|
|
5,356
|
4,965
|
|
|
|
|
|
|
Corporation tax paid
|
|
-
|
|
-
|
-
|
Investment in cases
|
6
|
(3,306)
|
|
(7,085)
|
(6,355)
|
Net
cash generated / (used in) from operating
activities
|
|
1,142
|
|
(1,729)
|
(1,390)
|
|
|
|
|
|
|
Cash flows from investing
activities
|
|
|
|
|
|
|
|
|
|
|
|
Finance income received
|
|
16
|
|
7
|
16
|
Net
cash generated from investing activities
|
|
16
|
|
7
|
16
|
|
|
|
|
|
|
Cash flows from financing
activities
|
|
|
|
|
|
|
|
|
|
|
|
(Repayments) / Proceeds from
borrowings
|
|
(1,250)
|
|
2,500
|
3,250
|
Interest paid
|
|
(724)
|
|
(464)
|
(1,060)
|
Net
cash (used in) / generated from financing
activities
|
|
(1,974)
|
|
2,036
|
2,190
|
|
|
|
|
|
|
Net
increase / (decrease) in cash and cash
equivalents
|
|
(816)
|
|
313
|
816
|
|
|
|
|
|
|
Cash and cash equivalents at the
beginning of the year
|
|
1,452
|
|
636
|
636
|
Cash and cash equivalents at the end of the
period
|
|
636
|
|
949
|
1,452
|
Unaudited notes to the financial statements for the period
ended 30 September 2024
1 Company information
Manolete Partners PLC (the
"Company") is a public company limited by shares incorporated in
England and Wales. The Company is domiciled in England and its
registered office is 2-4 Packhorse Road, Gerrards Cross,
Buckinghamshire, SL9 7QE. The Company's ordinary shares are traded
on the AIM Market.
The principal activity of the
Company is that of acquiring and funding insolvency litigation
cases.
2 Accounting policies
(a) Basis of preparation
The half-yearly financial statements
do not constitute statutory accounts within the meaning of Section
434 of the Companies Act 2006.
The interim condensed financial
statements for the six months ended 30 September 2024 have been
prepared in accordance with IAS 34 Interim Financial Reporting. The
interim condensed financial statements do not include all the
information and disclosures required in the annual financial
statements, and should be read in conjunction with the Company's
annual financial statements as at 31 March 2024.
The statutory accounts for the year
ended 31 March 2024 have been filed with the Registrar of Companies
at Companies House. The auditor's report on the statutory accounts
for the year ended 31 March 2024 was unqualified and did not
contain any statements under Section 498 (2) or (3) of the
Companies Act 2006.
(b) Going concern
The interim financial statements
relating to the Company have been prepared on the going concern
basis. The company has met each of its quarterly bank covenants
during the six months in H1 FY25.
After making appropriate enquires,
the Directors of the Company have a reasonable expectation that the
Company has adequate resources to continue in operational existence
for the foreseeable future and for at least one year from the date
of the signed interim financial statements. In reaching this
conclusion, the Directors have considered the position with respect
to covenant compliance, short-term cash forecast, the general
environment with respect to number of insolvencies in the UK
economy. For these reasons, they continue to adopt the going
concern basis in preparing the Company's interim financial
statements.
(c) Revenue recognition
Revenue comprises two elements: the
movement in fair value of investments and realised
consideration.
Realised consideration occurs when a
case is settled, or a Court judgement received. This is an agreed
upon and documented figure.
The movement in the fair value of
investments is recognised as Unrealised gains within Revenue. This
is management's assessment of the increase or decrease in valuation
of an open case, the inclusion of value for a new case and the
removal of the fair value of a completed case. These valuations are
estimated following the progress of a case towards completion and
also reflect the judgement of the legal team working on the case
(see Note 2(d). Significant Judgements and Estimates). Hence,
unrealised revenue is the movement in the fair value of the
investments in open cases over a period of time.
When a case is completed the
carrying value is a deduction to unrealised income and the actual
settlement value is recorded as realised revenue.
Revenue recognition differs between
a purchased case, where full recognition of the settlement is
recognised as revenue (including the insolvent estate's share) and
a funded case where only the Company's share of a settlement is
recognised as revenue. This differing treatment arises because the
Company owns the rights to the purchased case.
As revenue relates entirely to
financing arrangements, revenue is recognised under the
classification and measurement provisions of IFRS 9.
(d) significant judgements and
estimates
The preparation of the Company's
interim financial statements in accordance
with UK adopted International Accounting Standards requires the
Directors to make estimates and assumptions that affect the
reported amounts of assets and liabilities at the statement of
financial position date, amounts reported for revenues and expenses
during the period, and the disclosure of contingent liabilities at
the reporting date. However, uncertainty about these assumptions
and estimates could result in outcomes that could require a
material adjustment to the carrying amount of the assets or
liabilities affected in the future.
Estimates and judgements are
continually evaluated and are based on historical experiences and
other factors, including expectations of future events that are
believed to be reasonable under the circumstances.
The Company makes estimates and
assumptions concerning the future. The resulting accounting
estimates will, by definition, seldom equal the related actual
results. The estimates and assumptions that have a significant risk
of causing a material adjustment to the carrying amounts of assets
and liabilities within the next financial year are detailed
below.
Valuation of investments
Investments in cases are categorised
as fair value through profit or loss. Fair values are determined on
the specifics of each investment and will typically change upon an
investment progressing through a key stage in the litigation or
arbitration process in a manner that, in the directors' opinion,
would result in a third party being prepared to pay an amount
different to the original sum invested for the company's rights in
connection with the investment. Due to the nature of Manolete's
business model, an unrealised fair value gain will be recognised on
initial investment in a case. Thereafter, positive material
progression of an investment will give rise to an increase in fair
value and an adverse progression a decrease.
The key stages that an individual
case passes through typically includes: initial review on whether
to make a purchase or funding offer, correspondence from the
Company in-house lawyer, usually via externally retained
solicitors, to the opposing party notifying them of the Company's
assignment or funding of the claim, a fully particularised Letter
Before Action and an invitation to without prejudice settlement
meetings or mediation, if the opposing party does not respond then
legal proceedings are issued. Further evidence may be gathered to
support the claim. Eventually a court process may be entered into.
The progress of a case feeds into the directors' valuation of that
case each month, as set out below.
In accordance with IFRS 9 and IFRS
13, the Company is required to recognise live case investments at
fair value at the half year and year end reporting periods, at 30
September and 31 March each year.
The Company undertakes the following
steps:
• On a weekly basis, the internal
legal team report developments into the Investment Committee on a
case-by-case basis in writing. Full reviews then take place on a
monthly basis to review progress on all live cases, on a
case-by-case basis.
• On a monthly basis, the directors
adjust case fair values depending upon objective case developments,
for instance: an offer to settle, mediation agreed, positive or
negative legal advice. These adjustments to fair value may be an
increase or decrease in value or no change required;
• At reporting period ends, a sample
of open case investments for which written assessments are obtained
from external solicitors or primary counsel working on the case on
behalf of the Company.
In all cases, a headline valuation
is the starting point of a valuation from which a discount is
applied to reflect legal advice obtained, strength of defendant's
case, the likely amount a defendant might be able to pay to settle
the case, progress of the case through the legal process and
settlement offers.
Movements in fair value on
investments in cases are included within revenue in the Statement
of Comprehensive Income. Fair value gains or losses are unrealised
until a final outcome or stage is reached. At 30 September 2024
there were 413 open cases, of these 369 had a valuation of less
than £100k. These cases are not expected to have an individually
material impact on the business when they are settled. The
remaining 44 cases make up £23.3m of the Investments and are
material to the business, the significant judgements and estimates
in their valuations at the balance sheet date were as
follows:
1.
Judgements:
1.1 The amount that cases are
discounted to recognise cases being settled before they are taken
to Court, based on the facts of each case and management's
judgement of the likely outcome.
1.2 Litigation is inherently
uncertain. The Company seeks to mitigate its risk by: seeking
to settle cases as early as possible. Nevertheless, the risk and
uncertainty can never be completely removed. The key inputs are:
the headline claim value, the likely settlement value, the opposing
party's ability to pay and the likely costs in achieving judgement.
These inputs are inter-related to an extent.
1.3 The Company accrues for future
legal costs on the basis that cases will be settled before trial
which is how the vast majority of cases completed to date have been
settled. When it becomes clear a case will progress all the way to
trial then the additional costs are accrued at this point on a
case-by-case basis.
1.4 The Company classifies all legal
cases (non-cartel) as current assets as the intention and
expectation is to reach a settlement within 12 months. Cartel cases
are classified as non-current assets as the legal process for these
Competition Law cases is a longer-term process except where
settlement negotiations have commenced.
2.
Estimates:
2.1 All cases will be subject to the
internal key stages and regular fair value review processes as
described above. For the avoidance of doubt, the fair value review
requires an estimate to be made by senior management based upon the
facts and progress of the case and their experience. For a sample
selected by Management , an external opinion is requested from
counsel or a solicitor who is working on the case which provides an
independent description of the merits of the case.
These assessments include various
assumptions that could change over time and lead to different
assessments over the next 12 months.
2.2 Future legal costs have been
estimated on the estimated time the case will take to complete and
whether it will go to Court. Future results could be materially
impacted if these original estimates change either positively or
negatively.
2.3 Recovery of debts is based on
the Company's ability to recover assets owned by the counterparty.
Prior to case acceptance, a net worth review of the defendant is
undertaken to assess whether they own sufficient assets to support
the claim value. Cases that are settled without going to Court
typically recover in full, whilst those that result in Court cases
are less predictable in terms of full recovery.
2.4 The valuations assume that there
is no recovery for interest and costs except for the cartel cases
which do assume a figure for both costs recovery and interest
charge. If cases go to Court and result in a judgement in the
Company's favour, it is likely that the Company will be awarded
interest and costs.
Sensitivity analysis has not been
included in the financial statements, due to the vast amount of
inputs and number of variables which are inherently specific to
each case, making it impossible to provide meaningful data. Whilst
the Board considers the methodologies and assumptions adopted in
the valuation are supportable, reasonable and robust, because of
the inherent uncertainty of valuation, it is reasonably possible,
on the basis of existing knowledge, that outcomes within the next
financial year are different from the assumptions could require a
material adjustment to the carrying amount of the £39.5m of
investments disclosed in the balance sheet (Note 6). However, as an
indication we note that a 10% increase/(decrease) in the fair value
of our top 20 cases (excluding cartel cases) would result in an
increase/(decrease) in the fair value investment of +/-
£0.9m.
Approach to cartel case valuation:
Following publication of the ruling
in respect of an EU Competition test case (the "BT / Royal Mail"
case) we requested that our independent expert valuation firm apply
the assumptions contained within the test case ruling to the
valuation of Manolete's 22 cartel cases. Following the ruling and
the receipt of further case data, the directors consider that
additional discounting, or the use of a "tier based" system is no
longer required and the year-end valuation therefore represents
Manolete's percentage ownership of the overall case valuation. The
cartel case carrying valuation as at 30 September 2024 was £15.0m
(HY24 £15.2m).
Recoverability of trade receivables
The Company's business model
involves the provision of services for credit. The Company normally
receives payment for services it has provided once a claim has been
pursued and settled or decided in Court. The average time from
taking on a case to settlement is c.13.3 months although this can
vary significantly from case to case. As part of the settlement
agreement, the timing of payment of the award by the defendant to
the Company is agreed and this is a legally binding document.
Settlements can be received in full on the day of settlement or (at
Management's discretion) paid in instalments over a defined
settlement plan.
As such, Management applies a number
of estimates and judgements in the recording of trade receivables,
for example: in relation to default judgements Management assess
the likely recoverability and do not necessarily recognise the full
judgement.
The Company applies the simplified
approach in providing for expected credit losses under IFRS 9 which
allows the use of the lifetime expected credit loss provision for
all trade receivables. In measuring the expected credit losses,
trade receivables have been stratified by settlement type and days
past due. Expected lifetime expected credit loss rates are based on
the payment profiles of completed cases from April 2022 to December
2023. The Company attempts to assess the probability of credit
losses but seeks to mitigate its credit risk by undertaking
rigorous net worth checks before taking on a case. Occasionally
credit defaults do occur when counterparties default on an agreed
settlement payable by instalments. There is a concentration risk in
relation to the trade receivable of £6.0m which relates to a large
case completion in FY21. Repayments to date have been made
according to the agreed schedule. Based on Management's assessment
of the receivable no provision has been recognised against this
balance.
Recovery of receivables is closely
monitored by Management and action, where appropriate, will be
taken to pursue any overdue payments. The Company seeks to obtain
charging orders over the property of trade receivables as security
where possible. The receivables' ageing analysis is also evaluated
on a regular basis for potential doubtful debts. Where potential
doubtful debts are identified specific bad debt provisions are held
against these. It is the Directors' opinion that no further
provision for doubtful debts is required. Please see note 9 of the
interim accounts.
3 Segmental reporting
During the six months ended 30
September 2024, revenue was derived from
cases funded on behalf of the insolvent estate and cases purchased
from the insolvent estate, which are wholly undertaken within the
UK. Where cases are funded, upon conclusion, the Company has the
right to its share of revenue; whereas for purchased cases, it has
the right to receive all revenue, from which a payment to the
insolvent estate is made. Revenue arising from funded cases and
purchased cases are considered one business segment and are
considered to be the one principal activity of the Company. All
revenues derive from continuing operations and are not seasonal in
nature.
Net realised gains on investments in
cases represents realised revenue on completed cases.
Fair value movements include the
increase / (decrease) in fair value of open cases, the removal of
the carrying fair value of realised cases (in the period when a
case is completed and recognised as realised revenue) and the
addition of the fair value of new cases.
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
|
|
|
|
|
Net realised gains on investments in
cases
|
15,035
|
|
9,402
|
24,183
|
Fair value movements (net of
transfers to realisations)
|
(633)
|
|
1,828
|
2,112
|
Revenue
|
14,402
|
|
11,230
|
26,295
|
|
|
|
|
|
Arising from:
|
|
|
|
|
Purchased cases
|
14,356
|
|
12,034
|
26,985
|
Funded cases
|
46
|
|
(804)
|
(690)
|
Revenue
|
14,402
|
|
11,230
|
26,295
|
4 Analysis of expenses by
nature
Internal legal costs are included
within administrative expenses whereas external legal costs are
either capitalised as Investments for open cases or recognised as
cost of sales on completed cases. The breakdown by nature of
administrative expenses is as follows:
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Staff costs, including pension and
healthcare
costs
|
2,319
|
|
2,155
|
4,482
|
Bad debts including expected credit
losses
|
475
|
|
359
|
1,362
|
Professional fees
|
404
|
|
312
|
669
|
Marketing costs
|
194
|
|
232
|
365
|
Other costs, including office
costs
|
339
|
|
379
|
766
|
Total administrative
expenses
|
3,731
|
|
3,437
|
7,644
|
5 Finance expense
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Bank loan charges
|
758
|
|
548
|
1,283
|
Other loan interest
|
101
|
|
99
|
196
|
Total finance expense
|
859
|
|
647
|
1,479
|
6 Investments
Investments represent the expected
gross profit generated on the Company's ongoing portfolio of cases
on settlement. This incorporates the expected gross settlement less
the costs incurred to initially purchase the claim, costs incurred
to date, expected future costs, and the share of net gain due to
the Insolvency Practitioner.
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Investments brought
forward
|
40,196
|
|
36,462
|
36,462
|
Prepaid cost additions on live
cases
|
3,306
|
|
7,085
|
6,355
|
Realised prepaid costs
|
(3,327)
|
|
(5,940)
|
(4,733)
|
Fair value movement (net of
transfers to realisations)
|
(633)
|
|
1,828
|
2,112
|
Total investments
|
39,542
|
|
39,435
|
40,196
|
|
|
|
|
|
Current
|
28,251
|
|
25,905
|
28,903
|
Non-current
|
11,291
|
|
13,530
|
11,293
|
Total investments
|
39,542
|
|
39,435
|
40,196
|
7 Analysis of fair value
movements
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
New case investments
|
3,981
|
|
7,150
|
12,325
|
Increase in existing case fair value
(exc. cartel cases)
|
2,117
|
|
506
|
488
|
Decrease in existing case fair value
(exc. cartel cases)
|
(2,602)
|
|
(2,794)
|
(3,982)
|
Case completions
|
(4,115)
|
|
(3,175)
|
(6,811)
|
Increase in fair value attributable
to Cartel cases
|
(14)
|
|
141
|
92
|
Fair value movement (net of transfers to
realisations)
|
(633)
|
|
1,828
|
2,112
|
8
Non-cash adjustments to cashflows generated from
operations
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 32
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Fair value movements (net of
transfers to realisations)
|
633
|
|
(1,828)
|
(2,112)
|
Legal costs on realised
cases
|
3,326
|
|
5,939
|
4,733
|
Finance expense
|
859
|
|
647
|
1,479
|
Share based payments
|
191
|
|
144
|
336
|
Finance income
|
(16)
|
|
(7)
|
(16)
|
Non-cash adjustments to cashflows generated from
operations
|
4,993
|
|
4,895
|
4,420
|
9 Trade and other
receivables
|
30 September
2024
|
|
30 September
2023
|
31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Amounts falling due in more than one year:
|
|
|
|
|
Trade
receivables
Contract asset
|
9,738
2,340
|
|
9,150
2,456
|
11,738
2,465
|
Trade and other receivables due in more than one
year
|
12,078
|
|
11,606
|
14,203
|
|
|
|
|
|
Amounts falling due within one year:
|
|
|
|
|
Gross trade receivables
|
23,962
|
|
18,011
|
21,203
|
Less:
|
|
|
|
|
Specific provisions
|
(4,832)
|
|
(2,873)
|
(4,507)
|
Allowance for expected credit
loss
|
(2,054)
|
|
(2,577)
|
(1,838)
|
Trade
receivables
|
17,076
|
|
12,561
|
14,858
|
|
|
|
|
|
Prepayments
|
131
|
|
139
|
219
|
Trade and other receivables due within one
year
|
17,207
|
|
12,700
|
15,077
|
10
Trade and other payables
|
30 September
2024
|
|
30 September
2023
|
31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
Amounts falling due in more than one year:
|
|
|
|
|
Accruals - direct costs
Contract liability
|
5,911
1,732
|
|
5,314
1,705
|
6,651
1,783
|
Total trade and other payables due in more than one
year
|
7,643
|
|
7,019
|
8,434
|
|
|
|
|
|
Amounts falling due within one year:
|
|
|
|
|
Trade payables
|
907
|
|
611
|
1,325
|
Accruals - direct costs
|
7,797
|
|
4,226
|
6,714
|
Other creditors
|
950
|
|
562
|
1,058
|
Other taxation and social
security
|
127
|
|
122
|
138
|
Total trade and other payables due within one
year
|
9,781
|
|
5,521
|
9,235
|
11
Earnings Per Share
The Basic Earnings Per Share is
calculated by dividing the profit attributable to ordinary equity
holders by the weighted average number of ordinary shares
outstanding during the period. Diluted Earnings Per Share is
calculated by dividing the profit after tax by the weighted average
number of shares in issue during the period, adjusted for
potentially dilutive share options. The following reflects the
income and share data used in the Earnings Per Share
calculation:
|
6 months ended 30 September
2024
|
|
6 months ended 30 September
2023
|
Year
ended 31
March
2024
|
|
Unaudited
|
|
Unaudited
|
Audited
|
|
£'000s
|
|
£'000s
|
£'000s
|
|
|
|
|
|
Profit and total comprehensive
income for the period attributable to the equity owners of the
Company
|
(218)
|
|
625
|
933
|
|
|
|
|
|
Weighted average number of ordinary
shares
|
44,135,972
|
|
43,761,305
|
44,135,972
|
Basic Earnings Per Share
|
(0.49p)
|
|
1.43p
|
2.11p
|
|
|
|
|
|
Diluted weighted average number of
ordinary shares
|
45,128,057
|
|
45,975,328
|
45,128,751
|
Diluted Earnings Per Share
|
(0.49p)
|
|
1.36p
|
2.07p
|